Fredun Pharmaceuticals Limited has announced the establishment of a new manufacturing facility in Palghar, Maharashtra, marking the addition of its fifth facility.
According to a BSE filing, the new facility spans 40,000 sq. ft. and is expected to be operational by October 2026. This expansion is a significant step in the company’s growth journey.
The new facility will support key product categories, including veterinary products, nutraceuticals, and pharmaceutical formulations.
The company plans to undertake a further expansion of 50,000 sq. ft. under its strategic growth initiatives. This will enable Fredun Pharmaceuticals to enhance its efficiency and production scalability.
The company remains committed to maintaining high standards of quality, compliance, and innovation while strengthening its position as a leading manufacturing partner in the healthcare industry.
With a diverse range of products, including antihypertensives, antidiabetic, and antiretroviral drugs, Fredun Pharmaceuticals is a holistic healthcare provider.
The company’s expansion plans are expected to have a positive impact on its financial performance. In the FY25, Fredun reported total revenues of ₹ 456 Cr, with an EBITDA of ₹ 55 Cr and a PAT of ₹ 21 Cr. The new facility will enable the company to meet growing domestic and international demand.
The expansion of its manufacturing base reinforces Fredun Pharmaceuticals’ position as a leading pharmaceutical formulation manufacturing company in India.
With its strong manufacturing footprint, the company is well-positioned to capitalize on opportunities in the pharmaceutical and nutraceutical sectors.
Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. We are not registered financial advisors. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.
